Magnesium Taurate for Health & Longevity - Quick Reference Sheet

Magnesium Taurate for Health & Longevity

Created on 08/23/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 Audit

Magnesium taurate is an oral magnesium salt that supplies taurine. Blood-pressure and fasting-glucose effects are those of absorbable magnesium salts, not this salt alone. Direct human evidence is a single study with no comparison group. Main harms are loose stool and magnesium buildup when kidneys cannot clear it. Reasonable for blood pressure plus taurine; not a separately proven longevity agent. (Full Review)

Protocol

Practitioner pattern
200–350 mg elemental magnesium/day
Organic magnesium source aimed at blood pressure and sleep onset, not a unique drug
Time of day
Evening, or morning plus evening
Evening when sleep onset is the aim; morning-plus-evening splits suit blood-pressure repletion
Single versus split
Split doses
Split doses raise fractional absorption versus one large load
Time to effect
Blood Pressure Reduction
Median 12 weeks
Mixed-salt trials; taurate-specific timing is not established
Faster Sleep Onset
Days to a few weeks
When sleep-onset changes occur; untested for this form
Fasting Glucose in Type 2 Diabetes
Median 12 weeks
Mixed-salt trials in type 2 diabetes; not form-proven for taurate

Benefits

Contraindications
  • Severe chronic kidney disease (eGFR <30 mL/min/1.73 m²) or dialysis without specialist-directed magnesium use
  • High-degree atrioventricular block without a pacemaker
  • Myasthenia gravis with clinically unstable neuromuscular function
  • Known magnesium hypersensitivity
Key Interactions
  • Tetracyclines and quinolones (doxycycline, ciprofloxacin): Caution; at least 2 hours before or 4–6 hours after
  • Bisphosphonates (bone-density drugs; alendronate, risedronate): Caution; at least 2 hours; empty stomach
  • Levothyroxine: Caution; 4 hours separation
  • Gabapentin: Caution; separate doses
  • Loop and thiazide diuretics (furosemide, hydrochlorothiazide): Monitor
  • Potassium-sparing diuretics (spironolactone, triamterene): Caution when eGFR is reduced
  • Acid-suppressing drugs (omeprazole, pantoprazole): Monitor
  • Antihypertensives and other blood-pressure supplements (amlodipine, lisinopril, potassium citrate, extra taurine): Monitor
  • Calcium and high-dose zinc: Monitor; split from the magnesium dose

Risk & Side Effects

  • High: Gastrointestinal Loosening and Diarrhea
  • Medium: Hypermagnesemia in Reduced Kidney Function
  • Low: Additive Light-Headedness with Blood-Pressure Drugs
  • Speculative: Intact-Chelate or Taurine-Specific Harm at Usual Doses

Monitoring

Marker Target Why
Serum magnesium 2.0–2.3 mg/dL (0.82–0.95 mmol/L) Confirms the oral load is landing and not overshooting
RBC magnesium Track change from that person’s baseline; no established functional target Some clinics use it as a tissue proxy; not a validated surrogate
eGFR (creatinine or cystatin C) ≥60 mL/min/1.73 m² to continue unsupervised oral magnesium Gates hypermagnesemia risk
Home blood pressure Individual target, often <120/80 mm Hg if tolerated The main clinical surrogate this salt is chosen for
Fasting glucose or HbA1c Fasting glucose 70–90 mg/dL if pursuing metabolic optimization; HbA1c as that person’s trend Class magnesium signal is glucose, not HbA1c
Serum potassium 4.0–4.5 mmol/L when stacked with potassium citrate or sparing diuretics Dual-cation retention in low eGFR

Cadence: Baseline, then 4 weeks, then every 3–6 months while the dose is stable, or sooner if a diuretic, acid-suppressing drug, or antihypertensive is added

Qualitative Assessment

  • Stool form (formed sausage-shaped stool, Bristol 4, as the practical ceiling before dropping the dose)
  • Evening relaxation and sleep-onset latency without next-day grogginess
  • Absence of flushing, heavy legs, or new light-headedness on standing
  • Training recovery and muscle cramp frequency, interpreted cautiously because oral magnesium has not shown clear cramp prophylaxis in older adults